The Effect of Laparoscopic Sleeve Gastrectomy on Blood Phoenixin-14 Levels

NCT07004556 | Completed

• 1 other identifier: 2025/9-9
• Study Type: observational
• Target: 36
• Locations: 1 country
• Sites: 1

Brief Summary

Obesity is a major global health concern with a rising prevalence and numerous associated comorbidities. For the treatment of severe obesity, bariatric surgery stands as the most effective procedure. Bariatric and metabolic surgical procedures are applied even in the absence of comorbidities, particularly in patients with Type-III obesity and above. Currently, the most commonly performed bariatric metabolic surgical procedures are Laparoscopic Sleeve Gastrectomy (LSG) and Roux-en-Y gastric bypass. Animal studies have shown that phoenixin (PNX) in the paraventricular, arcuate, and solitary tract nuclei contributes to regulating food intake, and its intracerebral administration in rats increased food intake. The aim of this study is to investigate whether PNX-14 levels change before and after LSG in patients undergoing the procedure for severe obesity, given the potential association of PNX-14 with obesity and insulin resistance through its influence on the appetite center in metabolism.

Conditions

Obesity and Overweight; Obesity, Morbid

Keywords

Severe Obesity; Laparoscopic Sleeve Gastrectomy; Phoenixin-14; Obesity Surgery

Outcome Measures

Primary Outcomes (1)

• Laparoscopic Sleeve Gastrectomy effects blood Phoenixin 14 levels

  Phoenixin 14 blood levels can be effected by surgical intervention for severe obesity (laparoscopic sleeve gastrectomy)

  June 01,2025-October 01,2025

Study Arms (1)

Selective Laparoscopic Sleeve Gastrectomy Patients

Preoperative and postoperative blood samples obtained from the patients

Diagnostic Test: Preoperative blood sampling for determining Phoenixin 14 levels; Diagnostic Test: Postoperative blood sampling for determining Phoenixin 14 levels

Interventions

Preoperative blood sampling for determining Phoenixin 14 levels DIAGNOSTIC_TEST

In addition to routine blood draws for pre-operative preparations, 5 ml of blood will be collected.

Selective Laparoscopic Sleeve Gastrectomy Patients

Postoperative blood sampling for determining Phoenixin 14 levels DIAGNOSTIC_TEST

In addition to routine blood draws for postoperative controls, 5 ml of blood will be collected.

Selective Laparoscopic Sleeve Gastrectomy Patients

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Severe obesity patients scheduled for selective laparoscopic sleeve gastrectomy who have no associated medical problems

You may qualify if:

• Patients aged 18-65 years.
• Patients with severe obesity (Body Mass Index (BMI) ≥ 40 kg/m²) with no additional comorbidities (Type III, Type IV, and Type V obesity) who are scheduled for primary LSG.
• Patients who consent to participate in the study.

You may not qualify if:

• Patients who do not consent to participate in the study.
• Patients scheduled for primary obesity surgery other than LSG (e.g., Single Anastomosis Gastric Bypass, Roux-en-Y Gastric Bypass, Transit Bipartition, Single Anastomosis Sleeve Ileal Bypass, Single Anastomosis Duodeno-intestinal Bypass, Duodenal Switch).
• Patients with a BMI ≥ 35 kg/m² with associated medical problems (e.g., Diabetes Mellitus, Asthma, Chronic Obstructive Pulmonary Disease, Ischemic Heart Disease, Hypertension).
• Patients with a BMI ≤ 35 kg/m² who do not have a surgical indication.

Sponsors & Collaborators

• Kahramanmaras Sutcu Imam University: lead

Study Sites (1)

Elazığ Fethi Sekin City Hospital

Elâzığ, 23100, Turkey (Türkiye)

Location

Related Publications (12)

• Prinz P, Scharner S, Friedrich T, Schalla M, Goebel-Stengel M, Rose M, Stengel A. Central and peripheral expression sites of phoenixin-14 immunoreactivity in rats. Biochem Biophys Res Commun. 2017 Nov 4;493(1):195-201. doi: 10.1016/j.bbrc.2017.09.048. Epub 2017 Sep 11.

  PMID: 28911868 BACKGROUND

• Akdu S, Can U, Polat E. Investigation of serum phoenixin levels in patients with hypertension. Rev Assoc Med Bras (1992). 2022 Jun 24;68(6):814-819. doi: 10.1590/1806-9282.20220153. eCollection 2022.

  PMID: 35766697 BACKGROUND

• Cundubey CR, Cam SD. Serum Phoenixin-14 levels of women with polycystic ovary syndrome increase proportionally with BMI. Eur Rev Med Pharmacol Sci. 2023 Apr;27(8):3519-3525. doi: 10.26355/eurrev_202304_32125.

  PMID: 37140302 BACKGROUND

• Mukherjee K, Unniappan S. Mouse gastric mucosal endocrine cells are sources and sites of action of Phoenixin-20. Peptides. 2021 Jul;141:170551. doi: 10.1016/j.peptides.2021.170551. Epub 2021 Apr 17.

  PMID: 33862165 BACKGROUND

• Schalla M, Prinz P, Friedrich T, Scharner S, Kobelt P, Goebel-Stengel M, Rose M, Stengel A. Phoenixin-14 injected intracerebroventricularly but not intraperitoneally stimulates food intake in rats. Peptides. 2017 Oct;96:53-60. doi: 10.1016/j.peptides.2017.08.004. Epub 2017 Aug 24.

  PMID: 28844870 BACKGROUND

• Han Y, Jia Y, Wang H, Cao L, Zhao Y. Comparative analysis of weight loss and resolution of comorbidities between laparoscopic sleeve gastrectomy and Roux-en-Y gastric bypass: A systematic review and meta-analysis based on 18 studies. Int J Surg. 2020 Apr;76:101-110. doi: 10.1016/j.ijsu.2020.02.035. Epub 2020 Mar 6.

  PMID: 32151750 BACKGROUND

• https://bmjpublichealth.bmj.com/lookup/doi/10.1136/bmjph-2023-000245

  BACKGROUND

• Kirkil C, Aygen E, Korkmaz MF, Bozan MB. QUALITY OF LIFE AFTER LAPAROSCOPIC SLEEVE GASTRECTOMY USING BAROS SYSTEM. Arq Bras Cir Dig. 2018 Aug 16;31(3):e1385. doi: 10.1590/0102-672020180001e1385.

  PMID: 30133677 BACKGROUND

• https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight

  BACKGROUND

• Kassir R, Debs T, Blanc P, Gugenheim J, Ben Amor I, Boutet C, Tiffet O. Complications of bariatric surgery: Presentation and emergency management. Int J Surg. 2016 Mar;27:77-81. doi: 10.1016/j.ijsu.2016.01.067. Epub 2016 Jan 22.

  PMID: 26808323 BACKGROUND

• Eisenberg D, Shikora SA, Aarts E, Aminian A, Angrisani L, Cohen RV, de Luca M, Faria SL, Goodpaster KPS, Haddad A, Himpens JM, Kow L, Kurian M, Loi K, Mahawar K, Nimeri A, O'Kane M, Papasavas PK, Ponce J, Pratt JSA, Rogers AM, Steele KE, Suter M, Kothari SN. 2022 American Society of Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) Indications for Metabolic and Bariatric Surgery. Obes Surg. 2023 Jan;33(1):3-14. doi: 10.1007/s11695-022-06332-1.

  PMID: 36336720 BACKGROUND

• Purnell JQ. Definitions, Classification, and Epidemiology of Obesity. 2023 May 4. In: Feingold KR, Adler RA, Ahmed SF, Anawalt B, Blackman MR, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hamilton E, Hofland J, Jan de Beur S, Kalra S, Kaltsas G, Kapoor N, Kim M, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from http://www.ncbi.nlm.nih.gov/books/NBK279167/

  PMID: 25905390 BACKGROUND

MeSH Terms

Conditions

Obesity, Morbid; Obesity; Overweight

Condition Hierarchy (Ancestors)

Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseases; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 1 Day
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor, Associate (MD)

Study Record Dates

• First Submitted: May 26, 2025
• First Posted: June 4, 2025
• Study Start: July 1, 2025
• Primary Completion: November 1, 2025
• Study Completion: November 1, 2025
• Last Updated: January 13, 2026

Record last verified: 2026-01

Locations

TU (1)